Approval · Notice of Compliance 37411 · 2026
BEYFORTUS: Notice of Compliance 37411
Issued April 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37411
- Date
- April 27, 2026
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional drug substance manufacturing site and scale-up of the manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BEYFORTUS | Not yet assigned | — |
Medicinal ingredients
- NIRSEVIMAB 100 MG per ML
- NIRSEVIMAB 50 MG per 0.5ML